

## 2024 Areas of Interest for Bomedemstat

### Pre-Clinical:

- MPNs
  - Identify additive and/or antagonistic mechanisms of action between bomedemstat and novel combination partners
  - Nominate biomarkers for and/or elucidate biological mechanisms for biomarker-associated sensitivity to bomedemstat alone or in combination with other available or developing treatments
- MDS/AML
  - Identify additive and/or antagonistic mechanisms of action between bomedemstat and novel combination partners
  - Evaluate sensitivity of MPN-associated leukemias to treatment with bomedemstat as a single agent and elucidate biological mechanisms of action driving this sensitivity
  - Nominate biomarkers for and/or elucidate biological mechanisms for biomarker-associated sensitivity to bomedemstat alone or in combination with other available or developing treatments
- Sickle cell disease
  - Evaluate dosing regimens/schedules to establish the duration of inhibition that provides maximum therapeutic index (i.e. sufficient HbF induction to ameliorate SCD symptoms while maintaining adequate production of mature RBCs)
  - Identify additive and/or antagonistic mechanisms of action between bomedemstat and established or novel treatments for SCD
- Solid tumors
  - Identify and/or evaluate solid tumor indication(s) that are susceptible to treatment with bomedemstat as a single agent or in novel combinations. Studies that identify solid tumor indications and/or evaluate mechanisms in solid tumor indications where bomedemstat demonstrates single agent efficacy are of particularly high interest.